Clinical outcomes of muscle-invasive and metastatic, bladder, and urethral pure adenocarcinoma (BUAdenoCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
Brooke Kania(National Institutes of Health), Global Society of Rare Genitourinary Tumors, Adam Khorasanchi(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Marc Zerey(Vanderbilt University Medical Center), Zeynep İrem Özay(University of Utah), Dimitrios Stefanoudakis(APLA Health), Vikas Singh(Baptist Health Louisville), Neil Vaishampayan(Memorial Sloan Kettering Cancer Center), Amin Nassar(Yale Cancer Center), Sophia Sokol(University of Miami), Reza Lahiji(Emory University Hospital), Andrea B. Apolo(National Institutes of Health), Daniel Ang(National Cancer Centre Singapore), Inkeun Park(Ulsan College), Roger Li(Moffitt Cancer Center), Pablo Alvarez Ballesteros(Hospital Universitario 12 De Octubre), Rana R. McKay(University of California San Diego Medical Center), Kathryn E. Beckermann(Tennessee Oncology), Nosakhare Paul Ilerhunmwuwa(University of Pittsburgh Medical Center), Sebastiano Buti(University of Parma), Liliana Ascione(Harvard University)
Cited by 0
Related Papers
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
|Current Issues in Molecular Biology|2024|78
Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions
|Life|2024|25
VEGF inhibition in urothelial cancer: the past, present and future
|World Journal of Urology|2020|19